Raytone Biotechnology Co. Ltd. has described compounds based on oxidative stress and antiamyloid aggregations reported to be useful for the treatment of cataracts and presbyopia.
Zhuhai Yufan Biotechnologies Co. Ltd. has divulged mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, chronic obstructive pulmonary disease, AIDS, hemolytic anemia, psoriasis, scleroderma, systemic lupus erythematosus and ulcerative colitis, among others.
Allorion Therapeutics (Guangzhou) Co. Ltd. has identified phosphoramidate compounds targeting aldo-keto reductase family 1 member C3 (AKR1C3; 17β-HSD5) reported to be useful for the treatment of cancer.
Norwegian University of Science and Technology (NTNU) has synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, macular degeneration, osteoarthritis, osteoporosis, rheumatoid arthritis and Alzheimer’s disease, among others.
Université de Montréal has disclosed serine/threonine-protein kinase A-Raf, (ARAF) and/or B-Raf (BRAF) and/or RAF proto-oncogene serine/threonine-protein kinase (c-Raf) inhibitors reported to be useful for the treatment of cancer.
Maze Therapeutics Inc. has described sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, metabolic syndrome, chronic kidney disease and metabolic diseases.
Researchers at Biogen Inc. and Broad Institute Inc. have divulged glycogen synthase kinase-3α (GSK3A; GSK-3α) inhibitors reported to be useful for the treatment of cancer, neurological and metabolic diseases.
Norroy Bioscience Co. Ltd. has identified conjugates comprising fibroblast activation protein α (FAP)-targeting agents covalently linked to cytotoxic drugs or unlabeled or radiolabeled imaging agents through a linker acting as FAP ligands reported to be useful for diagnosis and treatment of cancer expressing FAP.
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized 3C-like proteinase (3CLpro, Mpro) (coronavirus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome infections.
Astrazeneca AB has disclosed CX3C chemokine receptor 1 (CX3CR1; CMKBRL1; GPR13) antagonists reported to be useful for the treatment of heart failure, among others.